Effects of Non-Steroidal Mineralocorticoid Antagonist (Finerenone) in Western Diet-Induced Kidney Disease

被引：0
|
作者：
Myakala, Komuraiah [1 ]
Ribeiro, Patricia de Carvalho [1 ]
Wang, Xiaoxin [1 ]
Korolowicz, Kyle E. [1 ]
Rodriguez, Olga C. [1 ]
Albanese, Chris [1 ]
Levi, Moshe [1 ]
机构：
[1] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2022年 / 33卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
SA-PO242
引用
收藏
页码：668 / 668
页数：1
相关论文
共 50 条
  • [41] Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K/Akt/eNOS signaling pathway in diabetic tubulopathy
    Yao, Lan
    Liang, Xianhui
    Liu, Yamin
    Li, Bingyu
    Hong, Mei
    Wang, Xin
    Chen, Bohan
    Liu, Zhangsuo
    Wang, Pei
    REDOX BIOLOGY, 2023, 68
  • [42] Finerenone, a novel selective non-steroidal mineralocorticoid receptor antagonist with a balanced cardiorenal tissue distribution confers pronounced end organ protection at low natriuretic doses
    Kolkhof, P.
    Delbeck, M.
    Kretschmer, A.
    Steinke, W.
    Hartmann, E.
    Baerfacker, L.
    Eitner, F.
    Albrecht-Kuepper, B.
    Schaefer, S.
    EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 : 210 - 210
  • [43] Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction
    Lachaux, Marianne
    Barrera-Chimal, Jonatan
    Nicol, Lionel
    Remy-Jouet, Isabelle
    Renet, Sylvanie
    Dumesnil, Anais
    Wecker, Didier
    Richard, Vincent
    Kolkhof, Peter
    Jaisser, Frederic
    Ouvrard-Pascaud, Antoine
    Mulder, Paul
    DIABETES OBESITY & METABOLISM, 2018, 20 (10): : 2399 - 2407
  • [44] Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
    DeFronzo, Ralph A.
    Bakris, George L.
    DIABETES OBESITY & METABOLISM, 2022, 24 (07): : 1197 - 1205
  • [45] Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease
    Liu, Licette C. Y.
    Schutte, Elise
    Gansevoort, Ron T.
    van der Meer, Peter
    Voors, Adriaan A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (08) : 1123 - 1135
  • [46] Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease
    Lima Posada, Ixchel
    Soulie, Matthieu
    Stephan, Yohan
    Palacios Ramirez, Roberto
    Bonnard, Benjamin
    Nicol, Lionel
    Pitt, Bertram
    Kolkhof, Peter
    Mulder, Paul
    Jaisser, Frederic
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (12): : e032971
  • [47] Suppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR-4628
    Ma, Frank Y.
    Han, Yingjie
    Nikolic-Paterson, David J.
    Kolkhof, Peter
    Tesch, Greg H.
    PLOS ONE, 2015, 10 (12):
  • [48] Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug–Drug Interaction Studies In Vitro and In Vivo
    Roland Heinig
    Michael Gerisch
    Anna Engelen
    Johannes Nagelschmitz
    Stephanie Loewen
    European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43 : 715 - 727
  • [49] Mineralocorticoid Receptors Mediate Western Diet-Induced Macrophage Polarization and Aortic Stiffness
    Jia, Guanghong
    Aroor, Annayya R.
    DeMarco, Vincent G.
    Sun, Zhe
    Bostick, Brian P.
    Meininger, Gerald A.
    Jaffe, Iris
    Sowers, James R.
    HYPERTENSION, 2014, 64
  • [50] FINERENONE Mineralocorticoid receptor (MR) antagonist Treatment of chronic kidney disease/diabetic nephropathy Treatment of heart failure
    Cole, P.
    DRUGS OF THE FUTURE, 2015, 40 (12) : 801 - 808
12345